Improving the stability of active ingredients through microencapsulation: OSDrC technology and contract formulation development.
Introducing the localization effect of OSDrC technology! Even active ingredients that become unstable when dispersed can be formulated into tablets.
The "OSDrC" technology, with its variable double-structured core, allows for precise and flexible control of the inner core, enabling the production of high-quality core tablets that surpass traditional methods and facilitating the development of various new dosage forms. Even active ingredients that become unstable when dispersed can be stabilized by localizing them in the inner core, allowing for tablet formulation in a manageable size while ensuring stability. 【Features】 ■ Stabilization of active ingredients that become unstable when dispersed is possible. ■ Reduction of cross-contamination between the inner core and outer layer is expected. ■ It is also possible to produce three-layer tablets that localize powder in three locations. ◎●◎Sample Presentation◎●◎ For those interested, we will send samples of tablets made using OSDrC technology. Please indicate your request for samples and the quantity in the inquiry form below. *: One person's sample consists of two sheets of PTP packaging (one sheet each of round and oblong tablets). Data demonstrating the improved stability of active ingredients that become unstable when dispersed, achieved through localization using OSDrC technology, can be viewed by downloading the PDF below.
Inquire About This Product
basic information
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（2）
Download All Catalogs
Company information
Sanwa Chemical Research Institute, as a member of the Suzuken Group focused on health creation, provides services aimed at improving the quality of life (QOL) for people who wish for better health, centered around its two main businesses: "pharmaceuticals" and "diagnostic drugs." In the "pharmaceuticals business," we are steadily building a track record with a focus on new drugs in the areas of diabetes and kidney/dialysis-related fields. In the "diagnostic drugs business," we are continuously developing and launching self-blood glucose meters, sensors, and diagnostic drugs for infectious diseases. Furthermore, by adding two more businesses— the "OSDrC (Osudrack) business" utilizing innovative formulation technology and the "contract manufacturing business" with advanced quality control systems— Sanwa Chemical Research Institute continues to evolve further.